Chezi Ganzel
Shaare Zedek Medical Center · Shearei Zedek Medical Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Chezi Ganzel as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 20:30 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05599360 · Vyxeos for Induction of Low- or Intermediate-risk.Shaare Zedek Medical Center · active not recruiting · Leukemia, Myeloid, Acute · principal investigator
- Ph2NCT04790474 · Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed and Refractory Multiple Myeloma Previously Treated With Daratumumab, Lenalidomide and BortezomibTel-Aviv Sourasky Medical Center · active not recruiting · Multiple Myeloma in Relapse, Refractory Multiple Myeloma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 20:30 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 20:30 UTC. The ranking covers the 200 most relevant of 6 PubMed records, and a shared surname and initials can bring in a namesake. All 6 on PubMed
- At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial.Br J Haematol · 202014 citationsRCR 0.6
- The Predictive Value of Thromboelastogram in the Evaluation of Patients with Suspected Acute Venous Thromboembolism.Acta Haematol · 202010 citationsRCR 0.7
- Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profiling.Leuk Res · 202210 citationsRCR 0.7
- CPX-351 +/- gemtuzumab ozogamicin as induction therapy for adult patients with newly diagnosed, favourable-intermediate risk, FLT3-ITD negative, AML: A pilot study.Br J Haematol · 20255 citationsRCR 1.1
- Characteristics and outcome of multiple myeloma patients presenting with anaemia only: A retrospective multi-centre study.Leuk Res · 20213 citationsRCR 0.2
- Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study.Blood Adv · 20230 citationsRCR 0.0